Sanofi, a company specialized in the pharmaceutical industry, will invest 129 million euros in a plant located in Cuautitlán Izcalli, State of Mexico, thus consolidating its regional leadership in the pharmaceutical branch.

This investment, added to the agreement between Sanofi Pasteur and the Government of Mexico, are the basis of the Azteca Project, a public-private partnership that will guarantee the annual supply of 32 million doses of influenza vaccines for 15 years.

Check here: Demands of industrial space with increasingly high standards

This project will allow the country to be self-sufficient in the production of vaccines against seasonal influenza, starting in 2024.

The investment is aimed at modernizing the Sanofi plant in the municipality of Ocoyoacac, as well as launching two upgrade projects, which will allow the production of state-of-the-art probiotics. In addition to this, the modernization and automation of its existing processes is also included.

Thus, Sanofi will promote scientific and technological innovation in Mexico, and will strengthen the value chains of the industrial and manufacturing sector in Mexico. These initiatives position the State of Mexico as a destination for productive investment.

Of interest: Investors have their sights set on the country's industrial real estate segment

Sanofi Mexico is a world leader in the production of vaccines. For 90 years, the pharmaceutical company has been present in Mexico and its products prevent 20 of the most well-known infectious diseases, including influenza, dengue, diphtheria, tetanus, and polio, among others.

In Solili you can check availability in Toluca, Cuautitlán, Tultitlán and Tepotzotlán

Original note